Figure 2.

DB-1310 combined with trastuzumab showed synergistic tumor inhibition in vivo. NOD/SCID mice inoculated with HCC1569 cells were intravenously administered with vehicle control or DB-1310 and/or trastuzumab at the indicated doses on day 0 (n = 5 mice/group). Tumor size (A) and body weight (B) during treatment were monitored twice weekly. Tumor volume was measured as the (length × width²)/2. Blood and tumor tissue samples were collected at indicated time points for single-dose pharmacokinetic profiles. The concentrations of ADC (DB-1310) in the serum (C) and tumor tissues (D) were quantified by ELISA. (E) The intratumoral concentration of the free payload was assessed using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The results represent two different experiments and are expressed as the mean ± SEM. ADC, antibody-drug conjugate; SEM, standard error of the mean.